Russian veterinary watchdog eyes Belarus a production site for anti-COVID vaccine for animals
<p> MINSK, May 19 - PrimePress. The Federal Service for Veterinary and Phytosanitary Surveillance (Rosselkhoznadzor) is considering the possibility of having the COVID-19 vaccine for animals Karnivak-Kov manufactured at the premises of Belarusian company BelVitunipharm, adviser to Rosselkhoznadzor CEO Yulia Melano told reporters. </p> <p> </p> <p> “Rosselkhoznadzor is considering setting up an additional production facility to make COVID-19 vaccines for animals at the Belarusian company BelVitunipharm,” Prime reports citing Melano as saying. </p> <p> </p> <p> This matter was in focus of an online meeting on 18 May 2021 featuring representatives of Rosselkhoznadzor's Federal Centre for Animal Health (VNIIZH), adviser to Rosselkhoznadzor's head Yulia Melano, and top managers of BelVitunipharm. </p> <p> </p> <p> According to estimates by the Russian side, the maximum volume of vaccine production at VNIIZH is 3 million doses per month, and this makes it possible to fully meet current demand. </p> <p> </p> <p> “At the same time, foreign countries are demonstrating a noticeably growing interest in the Russian prophylactic drug, which does not rule out the need to organize additional vaccine production sites in the future, including on the basis of the Belarusian pharmaceutical company,” Melano noted. </p> <p> </p> <p> The Karnivak-Kov vaccine is the only registered COVID-19 vaccine for animals in the world. Its development was financed by the Federal Centre for Animal Health of Russia. </p> <p> </p> <p> BelVitunipharm (before 2011 - Vitebsk Biofabrika) is a biological industry enterprise producing more than 150 items of pharmacological veterinary medicines and substances: sera, viral and bacterial vaccines, medicines. Its products meet international standards and are exported to Russia, Kazakhstan, Uzbekistan, Armenia, Tajikistan, Turkmenistan, Kyrgyzstan, Bahrain, Kuwait, Egypt and Turkey. End </p> <p> </p>
2021-05-20
Primepress
Russian veterinary watchdog eyes Belarus a production site for anti-COVID vaccine for animals
MINSK, May 19 - PrimePress. The Federal Service for Veterinary and Phytosanitary Surveillance (Rosselkhoznadzor) is considering the possibility of having the COVID-19 vaccine for animals Karnivak-Kov manufactured at the premises of Belarusian company BelVitunipharm, adviser to Rosselkhoznadzor CEO Yulia Melano told reporters.
“Rosselkhoznadzor is considering setting up an additional production facility to make COVID-19 vaccines for animals at the Belarusian company BelVitunipharm,” Prime reports citing Melano as saying.
This matter was in focus of an online meeting on 18 May 2021 featuring representatives of Rosselkhoznadzor's Federal Centre for Animal Health (VNIIZH), adviser to Rosselkhoznadzor's head Yulia Melano, and top managers of BelVitunipharm.
According to estimates by the Russian side, the maximum volume of vaccine production at VNIIZH is 3 million doses per month, and this makes it possible to fully meet current demand.
“At the same time, foreign countries are demonstrating a noticeably growing interest in the Russian prophylactic drug, which does not rule out the need to organize additional vaccine production sites in the future, including on the basis of the Belarusian pharmaceutical company,” Melano noted.
The Karnivak-Kov vaccine is the only registered COVID-19 vaccine for animals in the world. Its development was financed by the Federal Centre for Animal Health of Russia.
BelVitunipharm (before 2011 - Vitebsk Biofabrika) is a biological industry enterprise producing more than 150 items of pharmacological veterinary medicines and substances: sera, viral and bacterial vaccines, medicines. Its products meet international standards and are exported to Russia, Kazakhstan, Uzbekistan, Armenia, Tajikistan, Turkmenistan, Kyrgyzstan, Bahrain, Kuwait, Egypt and Turkey. End